Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia

2021 ◽  
Author(s):  
Natalia Dengina ◽  
Marina Chernykh ◽  
Catherine Degnin ◽  
Yiyi Chen ◽  
Ilya Tsimafeyeu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Patterns Of Care ◽  
Concurrent Chemoradiation ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

scholarly journals Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer

2020 ◽  
pp. 209-214
Author(s):  
N. V. Marinichenko ◽  
K. K. Laktionov ◽  
A. V. Nazarenko ◽  
E. V. Reutova ◽  
Merab S. Ardzinba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Concurrent Chemoradiation ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

For more than 10 years, there have been no significant improvements in treatment outcomes for patients with inoperable locally advanced non-small cell lung cancer. At the moment, the standard of treatment for this category of patients is concurrent chemoradiation therapy. At the same time, the 5-year overall survival rate varies in the range of 15–25%. This indicator contributes to the modernization of existing approaches, as well as the search for new ways in the treatment of patients with inoperable stage III non-small cell lung cancer.One of the promising areas is the combination of chemoradiation therapy with immunotherapy. Thus, the use of Imfinzi (durvalumab, AstraZeneca) as a consolidation therapy in the Phase III clinical trial PACIFIC demonstrated a reduction in the risk of death by about one third in comparison with the standard approach.We present a clinical case study of a patient with locally advanced non-small cell lung cancer who received treatment in the framework of concurrent chemoradiation therapy followed by immunotherapy with durvalumab, continuing until now. The result of the therapy is the complete response to the specific treatment, recorded according to PET-CT.Thus, the use of immunotherapy as consolidation therapy represents a promising strategy for improving outcomes after concurrent chemoradiation therapy in patients with inoperable stage III non-small cell lung cancer

Induction concurrent chemoradiation therapy for invading apical non-small cell lung cancer

2004 ◽  
Vol 52 (3) ◽  
pp. 120-126 ◽  
Author(s):  
Shinichiro Miyoshi ◽  
Keiji Iuchi ◽  
Kenji Nakamura ◽  
Katsuhiro Nakagawa ◽  
Hajime Maeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Concurrent Chemoradiation ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

scholarly journals Stage III Non–Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort

2018 ◽  
pp. 1-11 ◽  
Author(s):  
Vladmir C. Cordeiro de Lima ◽  
Clarissa S. Baldotto ◽  
Carlos H. Barrios ◽  
Eldsamira M. Sobrinho ◽  
Mauro Zukin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Concurrent Chemoradiation ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Consolidation Chemotherapy ◽  
Stage Iii Nsclc ◽  
Concurrent Chemoradiation Therapy

Purpose Of newly diagnosed patients with non–small-cell lung cancer (NSCLC), stage III accounts for 30%. Most patients are treated with concurrent chemoradiation therapy, but the addition of consolidation chemotherapy (CC) is debatable. We examined the effect of CC in Brazilian patients with stage III NSCLC treated in routine clinical practice. Methods We retrospectively collected data for patients from five different Brazilian cancer institutions who had stage III NSCLC and who were treated with chemoradiation therapy followed or not by CC. Eligible patients were age 18 years or older and must have been treated with cisplatin-carboplatin plus etoposide, paclitaxel, or vinorelbine, concurrently with thoracic radiation therapy (RT). Patients treated with surgery or neoadjuvant chemotherapy were excluded. The primary end point was overall survival (OS). Associations between CC and clinical variables and demographics were evaluated by using Pearson’s χ2 test. Survival curves were calculated by using the Kaplan-Meier method and were compared using the log-rank test. Univariable and multivariable analysis used a Cox proportional hazards model. Results We collected data from 165 patients. Median age was 60 years. Most patients were male (69.1%), white (77.9%), current or former smokers (93.3%), and had stage IIIB disease (52.7%). Adenocarcinoma was the most common histology (47.9%). Weight loss of more than 5% was observed in 39.1% and Eastern Cooperative Oncology Group performance status of 2 was observed in 14.6%. The only variable associated with CC was T stage ( P = .022). We observed no statistically significant difference in OS between patients treated or not with CC ( P = .128). A total delivered RT dose ≥ 61 Gy was the only variable independently associated with improved survival ( P = .012). Conclusion Brazilian patients with locally advanced NSCLC who were treated with standard treatment achieved OS similar to that reported in randomized trials. CC did not improve OS in patients with stage III NSCLC after concurrent chemoradiation therapy. An RT dose of less than 61 Gy had a negative effect on OS.

Sign in / Sign up

Export Citation Format

Share Document